Mode
Text Size
Log in / Sign up

Review of ADSC-Exos for diabetic foot ulcers lacks reported efficacy data or safety outcomes in this narrative synthesisStem cell exosomes may help heal diabetic foot ulcers

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that this narrative review lacks reported efficacy or safety data for ADSC-Exos in diabetic foot ulcers.

This narrative review examines the potential application of adipose-derived stem cell exosomes for treating diabetic foot ulcers and managing diabetes. The scope of the article focuses on these specific conditions without detailing the underlying clinical trials or observational studies that may have informed the discussion.

The authors indicate that critical methodological information was not reported. Specific data points such as the study population, sample size, intervention dosing, and primary outcomes are absent from the provided text. Because these details are missing, the review cannot quantify the clinical benefit or risk associated with this intervention.

Safety and tolerability profiles were also not reported in the source document. The authors do not provide specific adverse event rates or discontinuation data. Without these numbers, clinicians cannot assess the risk-benefit balance for patients considering this therapy.

The practice relevance remains unclear due to the lack of quantitative evidence. Readers should interpret this review as a qualitative overview rather than a source of definitive clinical guidance for diabetic foot ulcer management.

Diabetic foot ulcers are a serious complication of diabetes that can lead to infection and amputation. This review looked at the potential of exosomes derived from adipose stem cells to help heal these wounds. Exosomes are tiny particles that cells release to communicate with each other and can promote tissue repair.

The review gathered evidence from several studies on how these exosomes might work. The results suggest they could reduce inflammation and encourage new blood vessel growth, which are key steps in wound healing. While the findings are promising, the review notes that most of the research is still in early stages.

More high-quality clinical trials are needed to confirm how well these exosomes work in people and to determine the best way to use them. Researchers also need to study any possible side effects and long-term safety. This approach could one day become a valuable part of diabetes care.

What this means for you:
Exosomes from stem cells show promise for healing diabetic foot ulcers, but more research is needed.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Diabetes is a major global public health challenge. Diabetic foot ulcer (DFU), one of its most severe complications, imposes a substantial economic burden and severely impairs patients’ quality of life. Current treatment strategies often yield suboptimal outcomes, underscoring the urgent need for novel therapeutic approaches. Adipose-derived stem cell exosomes (ADSC-Exos) have emerged as a promising cell-free therapy with significant clinical potential. This review integrates the mechanisms through which ADSC-Exos facilitate diabetic wound healing with the phases of wound healing. It elucidates that ADSC-Exos function by alleviating oxidative stress, modulating inflammation, promoting angiogenesis, stimulating cell proliferation and migration, and suppressing excessive fibrosis. Additionally, this study organizes insights into how delivery strategies based on smart materials (e.g., hydrogels and bioscaffolds) and the latest physical modalities can overcome bottlenecks in clinical translation. This review aims to provide an integrated perspective for developing next-generation DFU therapies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.